Sanofi’s Sarclisa (isatuximab-irfc) + Carfilzomib and Dexamethasone Receives the US FDA’s Approval for the Treatment of R/R Multiple Myeloma

April 1, 2021 Auto Bot approval, FDA, receives, regulatory, Sanofi, Treatment 0

Shots:

  • The approval is based on P-III IKEMA study involves assessing of Sarclisa + carfilzomib and dexamethasone(kd) vs SOC in 302 patients with RRMM who had received 1 to 3 prior lines of treatment
  • The result demonstrated a reduction in the risk of disease progression or death by 45%. At pre-planned interim analysis, median PFS is not yet reached, ORR (86.6% vs 82.9%), CR (39.7% vs 27.6%), VGPR rate (33% vs 28.5%), OS were still immature
  • The FDA marks the second approval for Sarclisa, also approved in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adults with RRM

Click here to­ read full press release/ article | Ref: Sanofi | Image: Evaluate Pharma

The post Sanofi’s Sarclisa (isatuximab-irfc) + Carfilzomib and Dexamethasone Receives the US FDA’s Approval for the Treatment of R/R Multiple Myeloma first appeared on PharmaShots.